Literature DB >> 24154961

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

Christian Koelsche1, Felix Sahm, David Capper, David Reuss, Dominik Sturm, David T W Jones, Marcel Kool, Paul A Northcott, Benedikt Wiestler, Katja Böhmer, Jochen Meyer, Christian Mawrin, Christian Hartmann, Michel Mittelbronn, Michael Platten, Benjamin Brokinkel, Marcel Seiz, Christel Herold-Mende, Andreas Unterberg, Jens Schittenhelm, Michael Weller, Stefan Pfister, Wolfgang Wick, Andrey Korshunov, Andreas von Deimling.   

Abstract

Hot spot mutations in the promoter region of telomerase reverse transcriptase (TERT) have recently been described in several human tumor entities. These mutations result in an upregulation of the telomerase complex activity and thus constitute a relevant mechanism for immortalization of tumor cells. Knowledge of the TERT promoter status in tumors is likely to be of interest for molecular classification and as a potential target for therapy. We, therefore, performed a systematic analysis of TERT promoter mutations in 1,515 tumors of the human nervous system and its coverings including 373 pediatric and 1,142 adult patients. We detected a total of 327 mutations. TERT promoter mutations were exceedingly rare in tumors typically encountered in pediatric patients. In entities typically encountered in adult patients TERT promoter mutations were strongly associated with older age (p < 0.0001). Highest mutation frequencies were detected in gliosarcomas (81 %), oligodendrogliomas (78 %), oligoastrocytomas (58 %), primary glioblastomas (54 %), and solitary fibrous tumors (50 %). Related to other molecular alterations, TERT promoter mutations were strongly associated with 1p/19q loss (p < 0.0001), but inversely associated with loss of ATRX expression (p < 0.0001) and IDH1/IDH2 mutations (p < 0.0001). TERT promoter mutations are typically found in adult patients and occur in a highly tumor type-associated distribution.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24154961     DOI: 10.1007/s00401-013-1195-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  108 in total

1.  Association Between Prediagnostic Serum 25-Hydroxyvitamin D Concentration and Glioma.

Authors:  Victoria Zigmont; Amy Garrett; Jin Peng; Michal Seweryn; Grzegorz A Rempala; Randall Harris; Christopher Holloman; Thomas E Gundersen; Anders Ahlbom; Maria Feychting; Tom Borge Johannesen; Tom Kristian Grimsrud; Judith Schwartzbaum
Journal:  Nutr Cancer       Date:  2015-08-28       Impact factor: 2.900

Review 2.  The evolving molecular genetics of low-grade glioma.

Authors:  Sriram Venneti; Jason T Huse
Journal:  Adv Anat Pathol       Date:  2015-03       Impact factor: 3.875

3.  Recurrent 12q13-15 chromosomal aberrations, high frequency of isocitrate dehydrogenase 1 mutations, and absence of high mobility group AT-hook 2 expression in periosteal chondromas.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Ingeborg Taksdal; Bodil Bjerkehagen; Sverre Heim
Journal:  Oncol Lett       Date:  2015-05-11       Impact factor: 2.967

4.  Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.

Authors:  Benedikt Wiestler; David Capper; Volker Hovestadt; Martin Sill; David T W Jones; Christian Hartmann; Joerg Felsberg; Michael Platten; Wolfgang Feiden; Kathy Keyvani; Stefan M Pfister; Otmar D Wiestler; Richard Meyermann; Guido Reifenberger; Thorsten Pietsch; Andreas von Deimling; Michael Weller; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2014-07-15       Impact factor: 12.300

5.  Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.

Authors:  Hao You; Yao Wu; Kai Chang; Xiao Shi; Xin-Da Chen; Wei Yan; Rui Li
Journal:  CNS Neurosci Ther       Date:  2017-09-03       Impact factor: 5.243

6.  Molecular and translational advances in meningiomas.

Authors:  Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

7.  A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

Authors:  Fares Nigim; Shin-Ichi Esaki; Michael Hood; Nina Lelic; Marianne F James; Vijaya Ramesh; Anat Stemmer-Rachamimov; Daniel P Cahill; Priscilla K Brastianos; Samuel D Rabkin; Robert L Martuza; Hiroaki Wakimoto
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

8.  Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors.

Authors:  Zachary J Reitman; Christopher J Pirozzi; Hai Yan
Journal:  Acta Neuropathol       Date:  2013-12       Impact factor: 17.088

9.  TERT promoter mutations and prognosis in solitary fibrous tumor.

Authors:  Armita Bahrami; Seungjae Lee; Inga-Marie Schaefer; Jennifer M Boland; Kurt T Patton; Stanley Pounds; Christopher D Fletcher
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

10.  Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.

Authors:  Marcel Kool; David T W Jones; Natalie Jäger; Paul A Northcott; Trevor J Pugh; Volker Hovestadt; Rosario M Piro; L Adriana Esparza; Shirley L Markant; Marc Remke; Till Milde; Franck Bourdeaut; Marina Ryzhova; Dominik Sturm; Elke Pfaff; Sebastian Stark; Sonja Hutter; Huriye Seker-Cin; Pascal Johann; Sebastian Bender; Christin Schmidt; Tobias Rausch; David Shih; Jüri Reimand; Laura Sieber; Andrea Wittmann; Linda Linke; Hendrik Witt; Ursula D Weber; Marc Zapatka; Rainer König; Rameen Beroukhim; Guillaume Bergthold; Peter van Sluis; Richard Volckmann; Jan Koster; Rogier Versteeg; Sabine Schmidt; Stephan Wolf; Chris Lawerenz; Cynthia C Bartholomae; Christof von Kalle; Andreas Unterberg; Christel Herold-Mende; Silvia Hofer; Andreas E Kulozik; Andreas von Deimling; Wolfram Scheurlen; Jörg Felsberg; Guido Reifenberger; Martin Hasselblatt; John R Crawford; Gerald A Grant; Nada Jabado; Arie Perry; Cynthia Cowdrey; Sydney Croul; Gelareh Zadeh; Jan O Korbel; Francois Doz; Olivier Delattre; Gary D Bader; Martin G McCabe; V Peter Collins; Mark W Kieran; Yoon-Jae Cho; Scott L Pomeroy; Olaf Witt; Benedikt Brors; Michael D Taylor; Ulrich Schüller; Andrey Korshunov; Roland Eils; Robert J Wechsler-Reya; Peter Lichter; Stefan M Pfister
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.